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Abstract
Background: Health-related quality of life (HRQL) in hypertrophic cardiomyopathy (HCM) patients with implantable
cardioverter-defibrillators (ICDs) is largely unknown. The aim was to assess HRQL, including comparisons between
groups, using the questionnaire SF-36, and compare it to a Swedish age- and sex-matched population.
Methods and Results: Validated data on adult HCM patients with ICDs were used. The SF-36 response rate was
82.5 % and 245 patients (mean age 55.9 years, 70.2 % men) were analyzed using the Mann-Whitney U-test, t-test,
Spearman correlation and effect size calculations. In all SF-36 domains the patients’ score was lower (p-value
of <0.0001) than norms except for bodily pain. The general health domain showed the highest effect size (0.77) and
the impact was more pronounced in the SF-36 physical component summary score (0.62) than the mental
component summary score (0.46). Older age was correlated with lower scores on the physical component and
higher scores on the mental component. Atrial fibrillation and/or systolic heart failure were associated with worse
physical health. HRQL was similar in primary vs secondary prevention cases. Inappropriate ICD shock was associated
with worse mental health while appropriate therapy trended toward better mental health.
Conclusion: HCM patients with ICDs suffer from poor HRQL regardless of age, sex, or primary vs secondary
prevention indication. Atrial fibrillation and systolic heart failure are determinants of poor physical health.
Inappropriate shocks, but not appropriate therapies, are associated with poorer mental health.
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Background
Hypertrophic cardiomyopathy (HCM) in adults is char-
acterized by an abnormal thickening of the left ventricu-
lar wall (≥15 mm) that is not explained by other causes,
such as hypertension or aortic stenosis [1]. The preva-
lence is approximately 0.2 % and patients often suffer
from dyspnea, chest pain, dizziness, syncope, and palpi-
tations, especially upon exertion [1, 2]. Dyspnea may be
aggravated by a left-ventricular outflow obstruction,
tachycardia, or systolic heart failure (HF). A history of
atrial fibrillation (AF) warrants anticoagulation therapy
due to substantial risk of embolization stroke [1].
Ventricular tachyarrhythmias can be life-threatening
emergencies. An implantable cardioverter-defibrillator
(ICD) is a device implanted in the upper chest with a
transvenous lead fixated inside the right ventricle. In the
event of a dangerous tachyarrhythmia, the ICD can de-
liver a shock of energy via the lead directly to the heart
in order to convert the arrhythmia back to normal
rhythm. The ICD is also able to provide pacing support,
when needed, but most importantly, it can protect pa-
tients from sudden cardiac death (SCD) [3]. Survivors of
an episode of ventricular fibrillation or ventricular tachy-
cardia with hemodynamic compromise are recommended
an ICD for secondary prevention of SCD. Primary preven-
tion candidates are selected based on evaluation of estab-
lished risk factors: unexplained syncope, non-sustained
ventricular tachycardia, abnormal exercise response, ex-
treme myocardial thickness (≥30 mm), or a family history
of SCD [4, 5]. Recently, a novel risk calculator for HCM
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has been adopted in European guidelines; however guide-
lines also consider life-long risk of complications and psy-
chological health [1].
The concept “quality of life” is a cornerstone of vari-
ous treatment strategies and refers to patient-reported
outcome measures which are either generic or specific
to a certain disease state. Disease-specific instruments
usually focus on perceived health status rather than
quality of life, defined as “satisfaction with life.” Generic
health-related quality of life (HRQL) instruments include
both pure health status and domains reflecting quality of
life and are thus more holistic, but they may be less sen-
sitive than disease-specific questionnaires. Only generic
measures allow comparisons with the general popula-
tion. Therefore, we chose the widely used 36-item Short
Form (SF-36) Health Survey, a validated, self-reported
questionnaire, to assess generic HRQL in HCM patients
with ICDs [6, 7]. Several studies have addressed specific
concerns with general ICD patients based on various in-
dications, such as risk of anxiety, depression, and wors-
ened well-being [8–10]. In a study of a tertiary center
cohort, it appears that prior to the ICD era, HCM pa-
tients seem to have a deteriorated HRQL compared to
the general population [11]. The HCM subset of ICD pa-
tients may differ from other populations in age, burden
of symptoms, risk of ICD shocks, family history, comor-
bidities, and having a longer life expectancy.
The primary aim of this study was to compare the SF-
36 health profile in HCM patients with ICDs with age-
and sex-matched general Swedish norms for SF-36. The
secondary aims were to evaluate the impact on HRQL of
appropriate ICD therapy, inappropriate ICD shock, a
history of unexplained syncope, systolic HF, AF, device
complications requiring surgery, familial SCD, and sec-
ondary versus primary indication.
Methods
We previously reported a longitudinal follow-up of ICD-
related complications requiring surgery and those experi-
encing inappropriate shocks. In the present cross-sectional
study we assess HRQL in all living patients [12].
Data collection, validity, and ethics
In November 2012, we extracted data from the Swedish
ICD Registry on patients who had ever had an ICD im-
planted for a HCM indication. Since its inception in
1995, the Swedish ICD Registry has a validated 98 %
coverage of all implants in Sweden. The daily updated
online system from the Swedish Tax Authority Census
Bureau was used to identify living patients and exclude
deceased patients. All living patients were sent an enve-
lope with information about the study, a document to
sign their consent of participation in the study, the SF-
36 questionnaire in Swedish, and a postage-paid return
envelope. A total of three reminders during a period of
half a year were sent, followed by phone call to remind
those who had still not returned the questionnaire. After
the written informed consent was received, we retrieved
data from the validated National Patient Register which
contains data about diagnoses and hospital admissions
and is maintained by The Swedish National Board of
Health and Welfare.
Medical records were used to validate registry data
and were obtained from the different clinics between
December 2012 and April 2014. Data were collected
during visits to the hospitals/archives or by receiving
copies of medical records by regular mail. Categorization
of predefined variables was performed by the investiga-
tors (PM and SM).
SF-36 data were manually entered and missing items
were addressed by repeated contact with the patient to
gain complete answers whenever possible. Quality Metrics
(OptumInsight Life Sciences, Inc., RI) provided the SF-36
questionnaire with the license number QM015832. The
study was approved by Ethical Review Board in Stockholm
(document number 2012/1301-31/3) and complied with
current statements in the Declaration of Helsinki.
Statistical analyses
Descriptive data were expressed as frequencies, percent-
ages, means and standard deviations (SD), and a 95 % con-
fidence interval (CI) was used. Fisher’s exact test and t-test
were used for comparisons of categorical and continuous
variables, respectively. To analyze differences in SF-36
domains between groups we used the non-parametric
Mann-Whitney U-test. To analyze the continuous variable
age, non-parametric Spearman correlation was used in-
stead and in addition to Pearson correlation as a compari-
son to confirm results. Age was divided into the following
strata: 18-39 years, 40-59 years, and above 60 years. These
strata were analyzed using Kruskal-Wallis non-parametric
analysis of variance. The magnitude of group differences
was further determined by calculation of effect sizes (ESs).
ES of a between-group difference was estimated by calcu-
lating the mean difference, divided by the pooled standard
deviation (Cohen’s d). ES was interpreted according
to standard criteria: trivial (<0.20), small (0.20-0.49),
moderate (0.50-0.79), and large (≥0.80) [13]. Two-
sided p-values <0.05 were considered statistically signifi-
cant, whereas associations with p-values between 0.05 and
0.10 were considered a tendency. For statistical analyses
we used Excel 2010 (Microsoft Corporation, Redmond,
WA), SPSS version 22 (IBM, Armonk, NY), and SAS ver-
sion 9.2 (SAS Institute Inc., Cary, NC).
Definitions of variables
Appropriate ICD therapy was defined as overdrive-
pacing or discharge of 30-42 Joules due to a ventricular
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arrhythmia episode above the programmed detection
interval and duration. An ICD shock that is not due to
ventricular arrhythmia is called inappropriate and results
from inappropriate detection or interpretation of cardiac
potentials (atrial arrhythmias, T-wave oversensing) or
signals outside the heart (lead failure, myopotentials,
magnetic fields). Systolic HF implies symptoms like dys-
pnea or exercise intolerance and an echocardiogram
with an ejection fraction (EF) <50 %. Surgical complica-
tions are defined as those complications related to the
device system or the implant procedure, but not elective
replacement due to battery depletion. Risk factors that
would have been assessed in primary indication ICD pa-
tients are often not systematically addressed in second-
ary prevention cases, because the patient already has a
clear indication. Thus, analyses of risk factor subgroups
are limited to primary prevention patients. The risk
factors analyzed were non-sustained ventricular tachy-
cardia (NSVT), unexplained syncope, and a family his-
tory of SCD in a first degree relative before the age of
55 years.
SF-36 domains and validation
Generic HRQL was assessed by the SF-36 health survey
version 1 [7]. SF-36 is a patient-reported multidimen-
sional HRQL instrument developed in the Medical Out-
come Study and used in thousands of studies since the
introduction in the 1990s [6]. It is useful for estimating
the perceived burden of different medical conditions.
The instrument has 36 items measuring eight domains
that reflect a wide spectrum of physical and mental
health aspects: physical functioning (PF), role-physical
(RP), bodily pain (BP), general health (GH), vitality (VT),
social functioning (SF), role-emotional (RE), and mental
health (MH). Domain scores range from 0 to 100 with
higher values indicating better HRQL. The eight do-
mains can be aggregated into two summary measures:
the physical component summary (PCS) score and
the mental component summary (MCS) score. PCS
and MCS are calculated using norm-based scoring
with a mean of 50 and a value above 50 indicating
better HRQL than the general Swedish population. In
the Swedish validation of SF-36, internal consistency
reliability estimates (Cronbach’s α) for the eight do-
mains ranged between 0.79 (role-emotional) and 0.93
(bodily pain) [6].
The SF-36 profile in the study group was compared to
a general population sample randomly selected from the
Swedish SF-36 normative database (n = 8930; response
rate 68 %) [7]. The normative sample (validated in
Sweden 1991-92) was matched on sex and age and com-
prised 735 persons (516 males) with a mean age of
55.9 years (SD 14.8).
Results
Cohort characteristics
A total of 245 ICD patients with a validated diagnosis of
HCM reported their HRQL according to SF-36 (re-
sponse rate 82.5 %) as depicted in the flow-chart (Fig. 1).
Mean age was 55.9 years (SD 14.7, range 19-88 years),
and a majority was men (70.2 %). There were no gender
differences concerning mean age (men 56.4 years vs
women 54.8 years; t-test p = 0.420). Mean ages were
similar with regard to gender in the stratum; 18-39 years
(men 29.7 years vs women 31.1 years, p-value 0.507), 40-
65 years (men 51.1 years vs women 50.6 years, p-value
0.692), and older than 65 years (men 68.8 years vs
women 67.5 years, p-value 0.256). Characteristics of the
patients are shown in Table 1. There was no significant
difference in any of these variables between primary and
secondary indication patients. Among primary preven-
tion patients, 101 (56.1 %) reported a history of non-
sustained ventricular tachycardia, 43 (23.9 %) had a
family history of SCD, and 62 (34.4 %) had unexplained
syncope as a risk factor justifying the decision to implant
an ICD. All ICD device systems were implanted transve-
nously. Moreover, 72 (29.4 %) patients had a complica-
tion related to the ICD requiring surgical intervention.
Inappropriate ICD shock was experienced by 33 (13.5 %)
patients, and was often triggered by atrial arrhythmias.
A potentially life-saving, appropriate ICD therapy oc-
curred in 56 patients (22.9 %).
HRQL in the ICD cohort compared to general population
norms
All SF-36 scales showed a lower HRQL in HCM patients
with ICDs compared to sex- and age-matched popula-
tion norms (Table 2 and Fig. 2). There was a marked sta-
tistically significant (p < 0.001) difference for all scales
except BP (p = 0.550). The effect size between the study
cohort and the matched population norms with regard
to the significant differences varied between 0.35 (RE)
Fig. 1 Flow-chart of SF-36 questionnaire inclusion in hypertrophic
cardiomyopathy patients with implantable defibrillators
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and 0.77 (GH). PCS effect size was 0.62 and MCS 0.46,
respectively. Thus, effect sizes were small to moderate
and only approached large with regard to GH. Men and
women reported roughly equal SF-scores but men had a
tendency to higher PF scores (p = 0.053). Increasing age
was associated with lower scores on PF, RP, and PCS,
and higher scores on MH and MCS. Age had significant
influence (Spearman coefficients) on PF (r = -0.33; p <
0.001), RP (r = -0.18; p = 0.003), MH (r = 0.13; p = 0.038),
PCS (r = -0.30; p < 0.001), and MCS (0.14; p = 0.024).
Younger patients reported higher scores on the physical
scales PF, RP, and PCS, while older patients scored
higher on the mental scales MH and MCS. There were
significant differences on PF, PCS and MCS among the
age strata 18-39 years, 40-59 years, and 60 years.
HRQL subgroup analyses
Patients in the ICD cohort were dichotomized into sub-
groups according to clinical markers and between-group
differences in HRQL were tested. Outcomes showing a
significant (p < 0.05) or a tendency (p < 0.10) towards a
significant difference with regard to AF, systolic HF, ap-
propriate ICD therapy, and inappropriate ICD shock are
reported in Table 3 along with effect size. Patients with a
history of AF reported significantly worse physical health
(PF, RP, GH, PCS), worse SF, and a borderline trend to-
wards worse BP. Effect sizes were in the small range, but
estimates for PF and PCS were close to the limit for
moderate ES. Patients with a history of AF were 7.4 years
older (p < 0.001) than patients without AF. Systolic HF
was also associated with a deteriorated physical health
(PF, RP, GH, PCS) and ESs were small to moderate.
There was a tendency towards worse VT and SF with
small ESs. Mean age was 4.6 years higher in HF patients
compared to patients without HF (p-value = 0.053).
HCM patients who experienced appropriate ICD ther-
apy had better mental health with a small effect size and
MCS showed the same trend. Age was not different be-
tween the two categories, regardless of the history of ap-
propriate ICD therapy (p = 0.290). Mental health tended
to be worse (RE, VT, SF, MCS) among patients who had
experienced inappropriate shock(s). There was no age
difference between those who had experienced an in-
appropriate shock or not (p = 0.381).
Comparison of patients with secondary versus primary
indication showed no significant difference in SF-36
scores, but there was a tendency towards better vitality
(p = 0.07; ES 0.28) among secondary preventive patients.
Subgroup analysis of primary prevention patients with
the risk factor NSVT or familial SCD showed no signifi-
cant difference in the SF-36 domains. Patients with or
without a history of syncope had similar SF-36 scores
but syncope patients showed a tendency towards worse
Table 1 Characteristics of 245 hypertrophic cardiomyopathy
patients with implantable defibrillators
Age, mean (years) 55.9 (SD 14.7)
18-39 years 38 15.5 %
40-65 years 92 37.6 %
≥65 years 115 46.9 %
Male 172 70.2 %
Primary prevention 180 73.5 %
Diabetes mellitus 18 7.3 %
Hypertension 26 10.6 %
Stroke 23 9.4 %
Myocardial infarction 4 1.6 %
Alcohol septal ablation 17 6.9 %
Myectomy 16 6.5 %
Valvular surgery 8 3.3 %
Atrial fibrillation 87 35.7 %
Heart failure 48 19.6 %
Table 2 SF-36 score in hypertrophic cardiomyopathy patients with implantable defibrillators compared to general Swedish
population norms
SF-36 domains Cohort mean SD 95 % CI Effect size Norm mean SD 95 % CI p-value
Physical functioning 66.6 27.6 63.1-70.0 0.62 82.1 22.4 80.5-83.8 <0.0001
Role physical 57.4 43.6 52.0-62.9 0.46 76.0 37.1 73.2-78.7 <0.0001
Bodily pain 70.7 29.4 67.0-74.4 0.08 72.9 27.3 70.9-74.9 0.550
General health 53.7 25.5 50.5-56.9 0.77 72.4 23.1 70.7-74.1 <0.0001
Vitality 51.8 26.2 48.5-55.1 0.67 68.7 24.4 66.9-70.5 <0.0001
Social functioning 75.1 26.9 71.7-78.5 0.52 87.7 21.3 86.2-89.3 <0.0001
Role emotional 70.1 40.8 64.9-75.2 0.35 82.9 32.0 80.5-85.3 <0.0001
Mental health 71.8 22.9 69.0-74.7 0.47 81.7 18.8 80.3-83.1 <0.0001
Physical Component Summary 40.8 12.4 39.3-42.4 0.62 47.9 10.5 47.1-48.7 <0.0001
Mental Component Summary 45.5 12.9 43.9-47.1 0.46 50.8 10.2 50.0-51.6 <0.0001
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GH (p = 0.07; ES 0.27). Patients who had undergone sur-
gical procedures due to device system complications had
similar SF-36 scores compared to other patients.
Discussion
Hypertrophic cardiomyopathy patients with ICDs report
a poor HRQL. The generic instrument SF-36 showed
lower levels in all eight domains compared to general
Swedish age- and sex-matched population norms. The
difference in scores was highly significant (p < 0.001) for
all domains and their physical and mental component
summary components, except bodily pain. Effect sizes
varied from small to moderate with the largest value in
the GH domain (0.77). Physical component summary
was moderately affected (0.62) while MCS was smaller
(0.46); thus the effect on HRQL was even more pro-
nounced on physical domains. The results confirm pre-
vious findings presented more than 15 years ago from a
highly specialized British center. This British study in-
cluded 137 HCM patients (not an ICD cohort) and
showed a deteriorated health status (SF-36) that was
similar, or in mental domains even worse, to the severely
ill cardiac patients in the Medical Outcome Study [6].
Recently, a study of 19 HCM patients in Norway dem-
onstrated poor HRQL in both physical and mental do-
mains of SF-36 [14]. Another study showed that HCM
patients in general have disturbed sleep quality [15],
which may have a negative impact on both physical and
mental HRQL. The present nationwide study demon-
strates a markedly poor HRQL in HCM patients with
ICDs, despite modern treatment options including
pharmacological optimization, alcohol septal ablation,
septum reduction surgery, pacemakers, cardiac resyn-
chronization therapy and treatment of comorbidities [1].
Specific treatment like alcohol septal ablation can re-
duce gradients and suggests at least short-term improved
Fig. 2 Bar-chart SF-36 score in 245 hypertrophic cardiomyopathy patients with implantable defibrillators compared to Swedish age- and sex
matched population norms (n = 735)
Table 3 Subgroup analyses of hypertrophic cardiomyopathy patients with implantable defibrillators
SF-36 domains Atrial fibrillation Heart failure Appropriate therapy Inappropriate shock
p-value ES p-value ES p-value ES p-value ES
Physical functioning <0.001 0.47 <0.001 0.68 0.812 0.119
Role physical 0.002 0.38 0.003 0.48 0.211 0.382
Bodily pain 0.051 0.26 0.260 0.229 0.188
General health 0.004 0.38 0.023 0.33 0.864 0.118
Vitality 0.234 0.075 0.30 0.166 0.080 0.31
Social functioning 0.004 0.42 0.069 0.36 0.180 0.058 0.37
Role emotional 0.234 0.195 0.209 0.028 0.42
Mental health 0.288 0.681 0.033 0.30a 0.242
Physical Component Summary <0.001 0.48 <0.001 0.63 0.735 0.252
Mental Component Summary 0.495 0.884 0.076 0.27a 0.060 0.38
ES effect size
ahigher mental health and mental health summary scores (all other effect sizes were lower)
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HRQL [16]. However, no prospective study has so far ad-
dressed the long-term effects on HRQL of any interven-
tions in the specific groups of HCM patients with ICDs.
Patients with obstructive HCM may experience symptom
relief by pacing and subsequent outflow gradient reduc-
tion, or by a possible placebo effect. In our study, a total
of 33 patients underwent procedures to reduce outflow
obstruction, either by alcohol septal ablation or myect-
omy. Previous studies show that SF-36 scores on both
physical and mental domains improved during the first
year of pacing treatment [17–19]. HRQL ratings may thus
depend on time since ICD implant and might actually re-
flect individual coping strategies after the decision to im-
plant. In a general ICD population at least one year after
ICD implant, HRQL was significantly poorer than the
general population and scores on the SF-36 were lower on
the physical components than on the mental domains and
PCS [20]. Notably, only 3 % of the patients in our study
had their first implant during the last 12 months, which
implies that the HRQL assessment does not reflect tem-
porary changes due to the implant procedure and the rea-
sons for ICD implant. Although we live in a modern era
with advancements in specific HCM treatment and overall
cardiac care and comorbidities, the present study shows a
poor HRQL in HCM patients with ICDs. These patients
often have a reasonable life expectancy compared to other
ICD recipients and the association between clinical
markers and poor HRQL deserves further attention.
Atrial fibrillation
The poor HRQL in HCM patients with ICDs may be
partly explained by a history of AF. Subgroup compari-
sons in the present study showed that patients with a
history of AF (36 %) scored worse on SF-36 than those
without AF. This was especially pronounced with regard
to physical domains with significantly lower scores on
PF, RP, GH, SF, and PCS. The strongest impact was seen
on PF and PCS with a close to moderate effect size of
0.47 and 0.48 respectively. Thus, AF, defined as paroxys-
mal, persistent, or permanent, was a major determinant
of poor physical health in our study. AF is associated
with worse HRQL outcome in previous studies of other
patient groups and this finding aligns with the present
study [21]. The deleterious burden of symptoms due to
AF is well known in HCM [1]. AF is also the main cause
of inappropriate ICD shocks and contributes to HF. It is
therefore important to control rhythm whenever pos-
sible or, in permanent AF, to control the rate. Due to the
risk of embolization stroke, a history of AF warrants
anticoagulation therapy, independent of other risk fac-
tors [1]. AF is major cause of worsening symptoms in
HCM and requires vast healthcare resources. The pa-
tients with AF in this study were 7.4 years older than
those without AF, suggesting that more patients will
develop AF over an extended follow-up with the likeli-
hood of a concomitantly deteriorated HRQL. Thus, our
finding of a strong association between AF and poor
HRQL is expected, but we show that AF affects several
aspects of health, mental as well as physical, thus adding
to our knowledge about the consequences of AF in pa-
tients with HCM. This is a major clinical challenge, be-
cause a substantial proportion of HCM patients has or
will develop AF.
Heart failure
Patients with HF in the study scored worse on SF-36. A
history of HF was associated with significantly lower
scores in PF, RP, GH, and PCS and scores with border-
line p-values on the domains VT and SF. The effect size
varied from 0.30 (VT) to 0.68 (PF). Notably, the ES for
PF among HF patients was the strongest of all subgroup
comparisons in this study. HF patients were older (mean
4.6 years) but this likely has only a slight influence (t-test
p-value = 0.053). HCM patients in general often suffer
from dyspnea, attributable to outflow obstruction, dis-
turbed relaxation the left ventricle, arrhythmias, and co-
morbidities. As expected, the HF group with EF <50 %
reported poorer HRQL, especially with regard to phys-
ical domains. The SF-36 physical domains showed
higher ES-values and significance levels, which may be
explained by the impact of the patient’s deteriorating
clinical course of worsening HF. An EF <50 % in a HCM
patient is often a sign of poor overall prognosis. Our
findings are in accordance with experience from other
patients with HF. Indeed, in stable, chronic, symptomatic
HF patients, all SF-36 domains were affected, which paral-
lels findings among ICD recipients with HF [22–24]. In our
study, the 20 % of patients with HF defined as EF <50 %
turned out to have worse physical health. Furthermore, ex-
ertional dyspnea is common among all HCM patients and
may be an explanatory variable to the overall poor HRQL.
Due to the higher impact on physical domains in this
study, physical limitations should be evaluated thoroughly
in HCM patients along with their ICD device follow-ups.
Appropriate therapy and inappropriate shocks
Patients who had at least one appropriate therapy re-
ported significantly better mental health than those with-
out a potentially life-threatening ventricular arrhythmia
terminated by the ICD. The Mental component summary
showed a tendency in the same direction. This finding
comes as a relief, because events necessitating ICD
therapy can provoke anxiety or other concerns in the pa-
tient (for example driving restriction) and in the family.
On the other hand, knowing that ICD therapy may have
aborted a potentially lethal arrhythmia may have a positive
psychological impact on the patient (gratitude, relief, sense
of safety).
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Inappropriate shocks also affected mental health in a
negative way. They were associated with a significantly
lower RE score, while VT, SF and MCS showed the same
tendency. The effect sizes were small and this supports
the notion that many patients eventually learn to cope
with inappropriate shocks. Nevertheless, avoiding in-
appropriate shocks remains important as inappropriate
therapy may undermine ICD acceptance in both patients
and healthcare providers.
This cohort reported a rate of 5.3 % per year appropri-
ate therapy and 4.0 % per year inappropriate shocks,
which is within the range of the pooled data in the re-
view study [3, 12]. This suggests that results of the
present study are generalizable, even though none of the
studies in the review included HRQL assessment.
Primary versus secondary ICD indication
In this study there were no significant differences between
patients based on device indication but there was a ten-
dency towards better vitality among survivors after cardiac
arrest or ventricular tachycardia with hemodynamic com-
promise. Prophylactic ICD patients may cope differently
with the implant decision than secondary prevention pa-
tients. The latter group may feel gratitude because they
survived a life-threatening event, but they may also experi-
ence anxiety and depression. In another study of general
ICD recipients, there were lower SF-36 scores in primary
than in secondary prevention patients (significantly lower
in all domains except BP) [25]. This underscores the im-
portance of being aware of the vulnerability among pri-
mary prevention patients, including HCM patients. HRQL
aspects should be integrated in the overall evaluation of
the patient and in the decision-making process, first when
offering a potential candidate an ICD but also subse-
quently during follow-up. These strategies may include
support groups where patients can share experiences
under guidance of a healthcare provider, qualified coach-
ing in coping strategies, individual counselling, and opti-
mized management [26].
Interestingly, a French study on ICD recipients with
Brugada syndrome and similar age- and sex distribution
as patients in our present study sample showed no differ-
ence on BP and SF compared to the general population
[27]. Furthermore, a Dutch study confirmed that symp-
tomatic HCM was a determinant of lower scores on the
SF-36 physical component. However, mutation carriers
without manifest disease reported excellent HRQL, even
better than the general population [26, 28]. This highlights
that the burden of symptoms are the crucial determinants
of poor HRQL in HCM patients [29, 30].
There is convincing support from our study that poor
HRQL in HCM patients with ICDs can be mainly attrib-
uted to the burden of symptoms of the underlying dis-
ease and its different manifestations.
Familial SCD, non-sustained ventricular tachycardia, and
syncope
In our analyses of primary prevention patients we found
no specific impact on HRQL in the group of patients
who had a first-degree family member with SCD. Nei-
ther a history of NSVT nor unexplained syncope seems
to affect HRQL. It is also reassuring that patients who
underwent surgical procedures related to ICD device
system complications had similar HRQL as other pa-
tients, which suggests that, as a group, they cope well
with these interventions in the long term.
Sex differences
In the present study, no significant sex differences in SF-
36 scores were observed, although PF tended to be slightly
better in men. Likewise, another large study of general
ICD patients confirmed lower PF scores in females but
also lower VT scores, while no other differences in SF-36
were significant. In the same study, appropriate ICD
therapy was only associated with anxiety and lower GH
(p = 0.03) but inappropriate shock was not related to any
SF-36 domain [31]. This study supports the concept that
comorbidities, like AF and HF, rather than sex determine
poor HRQL. The decision to implant an ICD should be
based on individual risk and benefit estimation rather than
gender category.
Clinical perspectives
This study supports previous findings showing that the
major determinants of HRQL are related to the burden
of symptoms among HCM patients but not related to
sex. The decision to implant an ICD should take HRQL
aspects into consideration and include comorbidities as
a crucial determinant of poor HRQL. However, compli-
cations of ICD therapy do not have a significant impact
on HRQL and should not be considered a reason to
avoid an ICD implant. It is important to provide eligible
patients with thorough information before consent and
also to address potential ICD-related concerns during
follow-up, which may involve many years. ICD therapy
should include tailored device programming in order to
avoid inappropriate shocks and also psychological sup-
port [32, 33]. Concerning quality of life improvement,
overall management of HCM and comorbidities are im-
portant but remains challenging despite advances in
many therapeutic fields.
Strengths and weaknesses
This is the largest study on generic HRQL in HCM pa-
tients with ICDs. It is nationwide study of unselected pa-
tients using the well-validated SF-36 instrument with
age- and sex-matched comparisons with general popula-
tion norms. The response rate in the study was high and
register data were validated using medical records.
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Assessment of HRQL was done after the initial period of
ICD implant and is thus likely to reflect a more stable
phase for the patient. However, the cross-sectional de-
sign does not deal with the variation in HRQL over time
that is likely to occur in these patients, who often have
long clinical courses. In addition, HRQL is self-reported
and patients may have concerns that are not covered in
a generic health assessment questionnaire such as the
SF-36. Even though SF-36 is well validated, analyses on
associations with clinical variables lack definite causative
inference and are just associations.
Conclusions
Hypertrophic cardiomyopathy patients with ICDs have
poor HRQL compared to the general population. AF and
HF were major determinants of poor perceived health, es-
pecially physical health status. Appropriate ICD therapy
for ventricular arrhythmias implies similar HRQL scores,
while patients who receive inappropriate shocks report
lower mental health. There were no significant sex differ-
ences. In order to improve HRQL, HCM and its comor-
bidities must be better managed, ICD issues must be
carefully addressed, and patients should receive support to
promote their general well-being.
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